---
run_id: halo-evidence-vs-diagnosis-validation-v10-famous-sources-supplied-06
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
model_condition: famous_sources_supplied
run_number: 6
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 1024
seed: 602
prompt_source: condition packet (famous_sources_supplied) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a name-level list of famous source titles and authors, then the frozen Advisor prompt; no claims, summaries, source cards, or tension card - see run-packet.md
source_packet_sha256: d057ad83d3f7bf7e5568fa060310fc46d54ebd76e09ae17c88d4f64128eb21dd
condition_packet_sha256: d057ad83d3f7bf7e5568fa060310fc46d54ebd76e09ae17c88d4f64128eb21dd
output_file: model-outputs/famous_sources_supplied-06.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - famous_sources_supplied (run 06)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v10-v1`, condition `famous_sources_supplied`, run 6 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 602, on the frozen condition packet.

## Output

**Recommendation:** Run the Claim File Review.

**Why:**
Your current success is a "mirage" created by lagging indicators and sales incentives. The expansion bookings are driven by temporary pricing bundles (financial engineering) rather than value realization, and the usage spike is driven by managers auditing old files (administrative overhead) rather than adjusters solving claims (core value).

The most critical risk is the "explainability" gap in regulated health-liability and the tendency for adjusters to revert to manual notes. If the product cannot be defended by a user to their internal reviewer, it is not a workflow tool; it is a liability. The Usage Quality Sprint tracks *that* people are using it (which you already know is skewed), and the Commercial Cleanroom tracks *if* people will pay for it (which is a trailing indicator of value). Only the Claim File Review provides "ground truth" evidence of whether DraftPath actually improves the quality of a claim file or simply creates an artifact that is ignored or overridden. You cannot scale a product—or build a roadmap around it—until you know if the "next-action plans" are actually correct or merely plausible.

**The strongest reason against it:**
It is the slowest and most labor-intensive of the three validation options. It requires manual qualitative analysis of files, which provides a smaller sample size than the Usage Quality Sprint and lacks the immediate "hard dollar" validation of the Commercial Cleanroom. In a twelve-day window to lock a budget, it provides the least amount of "board-ready" quantitative data.

**Observable evidence that would change my mind:**
If the "regional carrier" churn (the two accounts already planning to remove DraftPath) is revealed to be caused by a specific, fixable technical bug or a missing integration rather than a failure of the product's core logic/explainability. If the problem is "the plumbing," then scaling or quantitative tracking becomes more urgent than qualitative file review.
